ArticleJournal of medicinal chemistry2025
Exceptionally Potent Chiral Anandamide Analogs.
Markos-Orestis Georgiadis, Elena Ferreras, Lipin Ji, Luana Assis Ferreira, John Hainline, Fei Tong, Vuong Q Dang, Alexandra Faragher, Anastasiia V Sadybekov, Laura M Bohn and 4 more
Abstract read
In one paragraphArticle in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Markos-Orestis GeorgiadisCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States.
Elena FerrerasCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States.
Lipin JiCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States.
Luana Assis FerreiraPsychological and Brain Sciences, Indiana University, Bloomington, Indiana 47405, United States.
John HainlinePsychological and Brain Sciences, Indiana University, Bloomington, Indiana 47405, United States.
Fei TongCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States.ORCID 0000-0003-2880-8135 Vuong Q DangDepartment of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, Florida 33458, United States.
Alexandra FaragherDepartment of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, Florida 33458, United States.
Anastasiia V SadybekovDepartment of Quantitative and Computational Biology, and Department of Chemistry, Bridge Institute, Center for New Technologies in Drug Discovery and Development, University of Southern California, Los Angeles, California 90089, United States.ORCID 0000-0003-3925-983X Laura M BohnDepartment of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, Florida 33458, United States.ORCID 0000-0002-6474-8179 Vsevolod KatritchDepartment of Quantitative and Computational Biology, and Department of Chemistry, Bridge Institute, Center for New Technologies in Drug Discovery and Development, University of Southern California, Los Angeles, California 90089, United States.ORCID 0000-0003-3883-4505 Andrea G HohmannPsychological and Brain Sciences, Indiana University, Bloomington, Indiana 47405, United States.
Alexandros MakriyannisCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States.ORCID 0000-0003-3272-3687 Spyros P NikasCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States.ORCID 0000-0001-5052-5292 Funding
Project 3 - In vivo pharmacology of cannabinoid receptor probesP01DA009158 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI Alexandros Makriyannis · 1994 to 2026
$26.0MComputational approaches to discover ligands with new chemotypes and functional propertiesR35GM153437 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI VSEVOLOD KATRITCH · 2024 to 2026
$899kNIDA NIH HHS P01 DA009158NIGMS NIH HHS R35 GM153437
6 · The paper itselfAbstract
We recently reported an innovative design approach that allowed us to obtain potent endocannabinoids with enhanced metabolic stability. Our design is characterized by the incorporation of chiral centers within the endocannabinoid prototypes
Indexed as
Arachidonic AcidsEndocannabinoidsPolyunsaturated AlkamidesAnimalsCannabinoid Receptor AgonistsHumansMolecular Docking SimulationRatsReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2StereoisomerismStructure-Activity RelationshipanandamideArachidonic AcidsCannabinoid Receptor AgonistsEndocannabinoidsPolyunsaturated AlkamidesReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2
Identifiers
PMID40954107
PMCPMC12915296
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390